To the Editors, Interpersonal and social rhythm therapy (IPSRT) is an effective psychotherapy approach for long-term management of bipolar disorder. 1 The main purpose of IPSRT is to regularize social and biological daily rhythms in order to promote mood stability and facilitate good sleep. The patients are required to record daily activities (eg, time out of bed, first contact with another person, meal times, bedtime) on the Social Rhythm Metric (SRM). 1 The SRM is useful for monitoring the dynamic interplay among instabilities in daily routines, patterns of social stimulation, sleep-wake times, and mood fluctuations. However, the SRM does not attach importance to the effect of ambient light.Light has profound effects on circadian rhythms and affects the mood directly. Ambient light exposure during the daytime improves mood and sleep quality. Light therapy has been found to improve bipolar depression but requires patients to sit in front of the device for 30 min to several hours. Therefore, as a simpler addition to their daily routine, when patients feel depressed or sad, we recommend them to increase ambient light exposure by opening the curtains in the morning or walking outside. Also, it is preferable to record the relationship between daily weather (sunny, cloudy, or rainy) and mood on the SRM.In contrast to the antidepressant effect of light, light deprivation has therapeutic effects for mania. Dark therapy (enforced darkness and rest from night to next morning) and virtual darkness therapy (blue light-blocking treatment by means of orange-tinted glasses) were found to improve manic symptoms of bipolar disorder. 2 We recently reported two cases of bipolar II patients with hypomania who responded to treatment with gray sunglasses used in the daytime. 3 Therefore, when the patients feel uplifted, we recommend them to reduce their ambient light exposure by turning down the room light or wearing the sunglasses. We suggest that this modified IPSRT via modulation of ambient light could keep mood more stable in comparison to the current IPSRT for patients with bipolar disorder.